StemCell Therapy

Cavitation Technologies, Inc. (CTi) (OTCQB: CVAT) (Berlin: WTC) and CBDual Biotechnology Corp announced today that the two companies have reached a comprehensive cross-licensing agreement. This agreement covers intellectual property involving application of technology and process patents to produce high quality pharmaceutical grade cannabis materials. The patented technology facilitates the production of cannabinoid formulations that may include Cannabidiol (CBD) and Tetrahydrocannabinol (THC) that can be easily mixed into fluids or medications providing increased stability of products and a much quicker enhanced absorption rate of medications.

Dr. Greg Rubin, CEO of CBDual Biotechnology Corp. commented, "The cannabis derived products market is growing rapidly in North America. Market Research Future reports indicate that U.S., Canada, and Mexico are dominant markets for cannabis products and these markets are expected to grow at 33% per annum from 2016 to 2021. Growing awareness about cannabis medicinal properties is also reflected in growing demand for new CBD based products. The development of consumer and medical products require the development of the best quality and utilization of the most innovative technologies in order to achieve ultimate results. This is only possible if we use the most advanced technological processes and our agreement with CTi enables us to manufacture the best quality CBD based oral care products by utilizing their advanced patented technology."

Global Technology Manager of CTi, Roman Gordon, stated that, "Intellectual property covered by this agreement between our companies enhances the development of cannabis based products and helps us expand into new consumer and medical markets. Cannabis based medicine is now emerging and being revisited as a potential source of treatments for conditions not addressed properly by synthetic substances," concluded Mr. Gordon

CTi's cross-licensing arrangement with CBDual Biotechnology Corp will oversee the infusion of cannabinoids in CBD based oral healthcare product line that includes mouthwash, toothpaste with cannabidiol and other unique formulations. Management also sees the potential to attract a number of potential licensees and distributors across multiple markets, including the therapeutic foods, CBD water, dietary supplements and pharmaceutical industries.

About CTi

Founded in 2007, the company designs and manufactures state-of-the-art, flow-through, devices and systems as well as develops processing technologies for use in edible oil refining, renewable fuel production, expeditious petroleum upgrading, algae oil extraction, alcoholic beverage enhancement and water treatment. As an add-on to its existing neutralization systems, the company's patented Nano Reactor allows refiners to significantly reduce both processing costs and environmental impact, while also increasing yield.

http://www.ctinanotech.com/

About CBDual Biotechnology Corp.

CBDual Biotechnology is a privately held, US based Biotechnology company with a proprietary technology for enhanced oral delivery of bioactive cannabinoids. This technology promotes good gums health and overall dental health due to higher effectiveness of the delivery methodology. Company was founded in 2016 and is headquarted in California with its R&D capability in Israel and Ukraine.

CBDual Biotechnology is a pharmaceutical research and development company, focused on the commercialization of cannabinoids (CBD) based oral hygiene products and for the treatment of gum disease, bad breath, pain and other disorders associated with oral health, including CBD mouthwash, CBD toothpaste and other unique pharmaceutical products. Company conducts medical research and clinical trials in their new clinical research center in California. Company's Medical Advisory Board has experienced, Board certified doctors and specialists that oversee and design clinical research and develop new products.

Welcome to CBDual

Forward Looking Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements regarding the anticipated installation and the timing of the installation, our intent to continue to focus on research and development, marketing and sales of our unique technology, our belief that our company is positioned for accelerated growth and the expected efforts to be made to enhance our shareholder's value. These forward-looking statements are based largely on the Company's expectations and are subject to a number of risks and uncertainties, certain of which are beyond the Company's control. Actual results could differ materially from these forward looking statements as a result of a variety of factors including, among others, the state of the economy, the competitive environment and our ability to perform the installation as anticipated and other factors described in our most recent Form 10-K and our other filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. In light of these risks and uncertainties there can be no assurances that the forward looking statements contained in this press release will in fact transpire or prove to be accurate. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Cavitation Technologies, Inc.

Contact:

Investor Relations Jessica Steidinger Jessica@ctinanotech.com Phone (818) 718-0905

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Read more:
Cavitation Technologies, Inc. (CVAT) Announces Cross Licensing ... - Equities.com

This entry was posted on February 16, 2017 at 10:46 am and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |